通过环状RNA介导的胆固醇代谢重塑治疗病理性淋巴管生成
本研究探讨环状RNA-KIF6(cKIF6)在病理性淋巴管生成中的作用及机制。在小鼠缝线角膜和炎症淋巴内皮细胞中cKIF6表达显著升高,沉默cKIF6可损害淋巴内皮细胞活力、增殖、迁移和成管,并在体内外减少淋巴管生成。机制上cKIF6作为miR-582海绵上调MSMO1表达、增加胆固醇含量,胆固醇生物合成抑制剂可减弱cKIF6过表达淋巴内皮细胞的增强表型。
要点
- cKIF6在小鼠缝线角膜和炎症淋巴内皮细胞中表达显著升高。
- 沉默cKIF6损害淋巴内皮细胞活力、增殖、迁移和成管,减少体内淋巴管生成。
- cKIF6通过miR-582/MSMO1轴增加胆固醇含量,抑制剂可减弱其促淋巴管生成表型。
核心结论
- cKIF6通过靶向胆固醇代谢调控淋巴管生成,是淋巴管生成相关疾病的有前景的治疗靶点。
研究设计与样本
- 研究评估小鼠缝线角膜和炎症条件下从青少年包皮分离的淋巴内皮细胞中cKIF6表达。
- 对沉默cKIF6后的淋巴内皮细胞进行活力、增殖、迁移和成管功能实验。
- 使用小鼠缝线角膜和Matrigel plug模型评估淋巴管生成。
- 机制研究探索cKIF6作为miR-582分子海绵及其下游对甲基固醇单加氧酶1(MSMO1)的影响。
主要发现
- cKIF6在小鼠缝线角膜和炎症淋巴内皮细胞中表达显著升高。
- 沉默cKIF6损害淋巴内皮细胞活力、增殖、迁移和成管,并在体外和体内模型中减少淋巴管生成。
- cKIF6作为miR-582海绵,导致淋巴内皮细胞中MSMO1表达升高和胆固醇含量增加。
- 胆固醇生物合成抑制剂减弱了cKIF6过表达淋巴内皮细胞增强的增殖、迁移和成管能力。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Lymphangiogenesis plays important roles in the pathogenesis of human diseases, including inflammatory ocular diseases, metabolic diseases, and cancers, by affecting lipid metabolism and immune homeostasis. Despite growing evidence showing that circular RNAs (circRNAs) act as the regulators of inflammatory and metabolic pathways, their roles in lymphatic dysfunction remain unclear. This study aims to explore the involvement of circRNA-KIF6 (cKIF6) in pathological lymphangiogenesis and elucidate the underlying mechanism. METHODS: The cKIF6 expression was evaluated in mouse-sutured corneas and lymphatic endothelial cells (LECs) isolated from juvenile foreskin under inflammatory conditions. Functional assays, including viability, proliferation, migration, and tube formation, were conducted on LECs after cKIF6 silencing. Lymphangiogenesis was evaluated using mouse-sutured cornea and Matrigel plug models. Mechanistic studies explored the role of cKIF6 as a molecular sponge for miR-582 and its downstream effect on methylsterol monooxygenase 1 (MSMO1). RESULTS: The cKIF6 expression was significantly elevated in mouse-sutured corneas and inflamed LECs. Silencing cKIF6 impaired LEC viability, proliferation, migration, and tube formation, leading to reduced lymphangiogenesis in both in vitro and in vivo models. Mechanistically, cKIF6 acted as a miR-582 sponge, resulting in elevated MSMO1 expression and increased cholesterol content in LECs. The augmented proliferation, migration, and tube formation abilities of cKIF6-overexpressing LECs were attenuated by the inhibitor of cholesterol biosynthesis. CONCLUSIONS: The cKIF6 regulates lymphangiogenesis by targeting cholesterol metabolism, making it a promising therapeutic target for lymphangiogenesis-related diseases.
引用
- Lu S, Liu Q, Ye F, et al. Treatment of Pathological Lymphangiogenesis via Circular RNA-Mediated Cholesterol Metabolism Remodeling. Invest Ophthalmol Vis Sci. 2025. PMID: 40214644. doi:10.1167/iovs.66.4.26
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。